HYPD vs. MEIP, IVVD, HURA, CGEN, GNLX, MGNX, ZNTL, PLX, BHST, and IKT
Should you be buying Hyperion DeFi stock or one of its competitors? The main competitors of Hyperion DeFi include MEI Pharma (MEIP), Invivyd (IVVD), TuHURA Biosciences (HURA), Compugen (CGEN), Genelux (GNLX), MacroGenics (MGNX), Zentalis Pharmaceuticals (ZNTL), Protalix BioTherapeutics (PLX), BioHarvest Sciences (BHST), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.
Hyperion DeFi vs. Its Competitors
Hyperion DeFi (NASDAQ:HYPD) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.
In the previous week, Hyperion DeFi had 1 more articles in the media than MEI Pharma. MarketBeat recorded 6 mentions for Hyperion DeFi and 5 mentions for MEI Pharma. Hyperion DeFi's average media sentiment score of 0.36 beat MEI Pharma's score of 0.19 indicating that Hyperion DeFi is being referred to more favorably in the media.
25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 10.9% of Hyperion DeFi shares are held by company insiders. Comparatively, 3.1% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
MEI Pharma has a net margin of 0.00% compared to Hyperion DeFi's net margin of -62,238.41%. MEI Pharma's return on equity of -77.00% beat Hyperion DeFi's return on equity.
Hyperion DeFi currently has a consensus price target of $2.00, indicating a potential downside of 86.65%. Given Hyperion DeFi's stronger consensus rating and higher possible upside, equities analysts plainly believe Hyperion DeFi is more favorable than MEI Pharma.
Hyperion DeFi has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.
MEI Pharma has lower revenue, but higher earnings than Hyperion DeFi. MEI Pharma is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.
Summary
Hyperion DeFi beats MEI Pharma on 8 of the 14 factors compared between the two stocks.
Get Hyperion DeFi News Delivered to You Automatically
Sign up to receive the latest news and ratings for HYPD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hyperion DeFi Competitors List
Related Companies and Tools
This page (NASDAQ:HYPD) was last updated on 9/12/2025 by MarketBeat.com Staff
